Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Apr 28, 2022
Virtual AGM online guide
Apr 28, 2022
Notice of Annual General Meeting/Proxy Form
Apr 27, 2022
Change in substantial holding
Apr 27, 2022
Appendix 4G
Apr 27, 2022
Annual Report to shareholders
Mar 25, 2022
FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
Mar 23, 2022
FDA approval for Phelan-McDermid IND and Phase 2 trial
Mar 11, 2022
Ethics approval for Angelman Phase 2 trial in Australia
Feb 25, 2022
Investor presentation 25 Feb 2022
Feb 25, 2022
FDA approval for Angelman IND and Phase 2 trial
Previous
1
2
3
4
Next
